Clinical Trial Update: SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults [Phase 2]

View source ↗

Summary

Pfizer conducted a Phase 2 safety, tolerability, and immunogenicity study of SA4Ag in Japanese adults with Staphylococcal infections; results were posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Staphylococcal Infections

Drugs mentioned

• SA4Ag (4-antigen Staphylococcus aureus vaccine)

Snippet

Sponsor: Pfizer | Conditions: Staphylococcal Infections | Phase 2 | Status: COMPLETED | Results posted: 2018-07-30